Pharmacokinetics and dynamics of penbutolol in humans: Evidence for pathway-specific stereoselective clearance

Abstract

The pharmacokinetics and dynamics of thed- andl-isomers of the beta-adrenergic blocking agent penbutolol were investigated in healthy human volunteers. In Study One, subjects received a single 40-mg oral dose ofl-penbutolol (the pharmacologically active stereoisomer), and matching placebo on two occasions. A mean peak serum penbutolol concentration of 268 ng/ml was reached at 0.9 h after dosing. Elimination half-life averaged 1.6 h, and total clearance 16.6 ml/min per kg body weight. Changes in blood pressure, ventricular rate, and rate of circumferential fiber shortening (Vcf) did not differ betweenl-penbutolol and placebo. In Study Two, subjects received 40 mgd-penbutolo,l-penbutolol, and placebo on three occasions. Total clearance ofd-penbutolol was higher than for thel-isomer (43.7 vs 15.9 ml/min/kg;PP<0.005). In contrast, direct conjugates ofl-penbutolol achieved higher serum concentrations than conjugates ofd-penbutolol. Alterations in blood pressure, ventricular rate, and Vcf ford-penbutolol,l-penbutolol, and placebo were quantitatively small. Thus the clearance of penbutolol after oral administration in humans is stereoselective, but the oxidative pathway is more stereosensitive than the parallel conjugative pathway. Penbutolol causes minimal alterations in parameters of cardiac function after single 40-mg doses in healthy humans.